Powell Will Vote With His Mind and Heart, Daco Says
Original Report
Gregory Daco, EY-Parthenon chief economist, says he thinks former Federal Reserve Chair Jerome Powell will not be afraid to dissent as a member of the board of governors. Daco speaks on "Bloomberg...
Gregory Daco, EY-Parthenon chief economist, says he thinks former Federal Reserve Chair Jerome Powell will not be afraid to dissent as a member of the board of governors. Daco speaks on "Bloomberg Surveillance." (Source: Bloomberg)
Glass House Analysis
Central bank policy decisions made in boardrooms cascade through the economy in ways that touch everyone. A quarter-point rate change might seem abstract, but it determines whether young families can afford homes, whether businesses can afford to hire, and whether retirees see meaningful returns on their savings. The tension between fighting inflation and maintaining employment represents a fundamental tradeoff in economic policy—one that invariably creates winners and losers.
The implications extend beyond the immediate news cycle. Every economic development creates ripples that affect employment, prices, and opportunities in ways that may not be immediately visible but are deeply felt. By tracking these connections, we can better understand how the economy truly works—not as an abstract machine, but as a human system shaped by and shaping the lives of millions.
Enjoyed this analysis?
Get the Glass House Briefing every morning—market news that actually makes sense, delivered free to your inbox.
No spam. Unsubscribe anytime.
More Stories
Judges block Alabama districts that would dilute Black vote in 2026 congressional elections
A three-judge panel found that the 2023 congressional district maps adopted by Alabama intentionally discriminated against Black voters.
A defense stock down big lately is primed for a turnaround. How to play a comeback with less risk
Northrop Grumman has suffered an eye-popping 30% collapse in under two months.
Goldman says this biotech stock will be a winner thanks to a one-of-a-kind treatment
Hemab Therapeutics is likely to gain ground as its treatment for a pair of rare bleeding disorders shows signs of efficacy, per Goldman Sachs.
Lilly Gets Back Into the Vaccine Business With New Deals
Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion as it looks to become a leader in infectious diseases. The drugmaker has been using cash from its obesity...